Hemophilia A – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Hemophilia A, an x-linked genetic disorder, is characterized by a factor VIII deficiency. Factor VIII primarily originates from the liver and is secreted into the bloodstream inactive, forming a complex with the von Willebrand factor. Other tissues, including the endothelium, also contribute to factor VIII production. In contrast, factor IX is exclusively produced by the liver. Among the enduring complications of hemophilia, chronic hemarthroses are frequently encountered. In cases of intra-articular bleeding, spontaneous resolution can occur or be facilitated by treatment during acute episodes. Numerous patients will encounter recurrent bleeding incidents, developing one or more target joints that often cause pain and limit their daily activities. These target joints are commonly found in the knee, elbow, and ankle. Over time, chronic synovitis and persistent hemarthroses can culminate in degenerative joint ailments, osteoarthritis, and the formation of osteophytes.

·       As per the USA Centers for Disease Control and Prevention (CDC), hemophilia is estimated that roughly 10 out of every 100,000 individuals are affected by hemophilia A.

 

Thelansis’s “Hemophilia A Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hemophilia A treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Hemophilia A across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Hemophilia A Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Hemophilia A – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Hemophilia A, Hemophilia A market outlook, Hemophilia A competitive landscape, Hemophilia A market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)